Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.320
-0.080 (-5.71%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Company Description

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.

Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.

Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics, Inc.
Outlook Therapeutics logo
Country United States
Founded 2010
IPO Date May 13, 2016
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Lawrence Kenyon

Contact Details

Address:
111 S. Wood Avenue, Unit #100
Iselin, New Jersey 08830
United States
Phone 609 619 3990
Website outlooktherapeutics.com

Stock Details

Ticker Symbol OTLK
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001649989
CUSIP Number 69012T206
ISIN Number US69012T3059
Employer ID 38-3982704
SIC Code 2836

Key Executives

Name Position
Lawrence A. Kenyon CPA EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary and Director
Jeffrey Evanson Chief Commercial Officer
Joel Prieve Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D. Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Jedd Comiskey Senior Vice President - Head of Europe

Latest SEC Filings

Date Type Title
Mar 28, 2025 424B3 Prospectus
Mar 20, 2025 S-3 Registration statement under Securities Act of 1933
Mar 14, 2025 8-K Current Report
Mar 12, 2025 SCHEDULE 13D/A Filing
Mar 7, 2025 EFFECT Notice of Effectiveness
Mar 7, 2025 424B3 Prospectus
Mar 3, 2025 SCHEDULE 13G Filing
Feb 28, 2025 S-3 Registration statement under Securities Act of 1933
Feb 28, 2025 8-K Current Report
Feb 14, 2025 10-Q Quarterly Report